Allocetra Cell Therapy – Talk Bio

Actionable Insights Powered by AI

Enlivex Stock Plunges 50% Following Mixed Phase II Sepsis Results for Allocetra Cell Therapy

1 year ago talkbio0Tagged Allocetra Cell Therapy, Enlivex, Phase 2 Clinical Trials, Septic Shock, Septicemia, Stock Plummet, Urinary tract infection

Enlivex Therapeutics, Allocetra Cell Therapy, Phase II Study, Sepsis Treatment, Stock Plummet, Mixed Results, Septic Shock, Urinary Tract Infection (UTI)